Serum glucagon-like peptide-1 and G-protein-coupled receptor levels are associated with albuminuria and kidney function in type 2 diabetes: A cross-sectional study

Keywords: diabetes mellitus type 2, diabetic nephropathies, albuminuria, glomerular filtration rate, cystatin C, glucagon-like peptide 1, receptors, G-protein-coupled, biomarkers.

Abstract

The relationship of serum glucagon-like peptide-1 (GLP-1) and G-protein-coupled receptor (GPCR) with kidney-related outcomes continues to be poorly studied. The purpose of this study was to determine whether serum GLP-1 and GPCR are related to urinary albumin-to-creatinine ratio (uACR), estimated glomerular filtration rate (eGFR), and cystatin C in patients with type 2 diabetes mellitus (T2DM).

Methods. A total of 150 participants were included in this cross-sectional study and divided into three groups: the healthy subjects (Control group), T2DM patients with albuminuria stage A1 (T2DM-A1 group), and T2DM patients with albuminuria stage A2/A3 (T2DM-A2/A3 group). There were 50 subjects in each group. The clinical information was collected: fasting glucose, HbA1c, insulin, urea, creatinine, eGFR, uACR, cystatin C, GLP-1, and GPCR values. Serum GLP-1, GPCR, and cystatin C were measured using sandwich ELISA kits. Groups were compared using non-parametric testing. Analysis of Spearman correlation was utilized in the diabetic cohort. Linear regression adjusted for age, BMI, diabetes duration, and HbA1c was conducted to identify independent associations of GLP-1 and GPCR with uACR and eGFR.

Results. GLP-1 and GPCR concentrations were gradually increasing from Сontrol group to group T2DM-A1 and group T2DM-A2/A3. Within the diabetic cohort, GLP-1 and GPCR were positively correlated with uACR and cystatin C and negatively correlated with eGFR. After adjustment for covariates, GLP-1 was associated with higher log-transformed uACR (standardized = 0.529, p < 0.001) and lower eGFR (standardized = -0.415, p < 0.001). Similarly, GPCR also showed a positive correlation with log-transformed uACR (standardized = 0.319, p = 0.002) and a negative correlation with eGFR (standardized = -0.365, p = 0.002).

Conclusions. Circulating GLP-1 and GPCR levels were associated with higher albuminuria and lower eGFR in T2DM. GLP-1 demonstrated a stronger association with albuminuria, while GPCR displayed a comparable negative association with kidney function. The study’s findings offer evidence for a cross-sectional GLP-1-GPCR kidney-related biomarker profile that characterizes the albuminuric T2DM phenotype and call for longitudinal studies to confirm the clinical utility of these markers.

       

Downloads

Download data is not yet available.

References

Uma A, Sivaraman S, Manoharan R, Periasamy P. Diabetic Kidney Disease in Type 2 Diabetes: A Comprehensive Review of Epidemiology, Pathophysiology, and Therapeutic Advances. J Pharm Bioallied Sci. 2025;17:33-5. doi: 10.4103/JPBS.JPBS_1059_25.

Diabetes* ADAPPC for, Bajaj M, McCoy RG, Balapattabi K, Bannuru RR, Bellini NJ, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49 Supplement_1:S246–60. doi: 10.2337/DC26-S011.

Christofides EA, Desai N. Optimal Early Diagnosis and Monitoring of Diabetic Kidney Disease in Type 2 Diabetes Mellitus: Addressing the Barriers to Albuminuria Testing. J Prim Care Community Health. 2021;12:21501327211003684. doi: 10.1177/21501327211003683.

Wani ZA, Ahmed S, Saleh A, Anna VR, Fahelelbom KM, Raju SK, et al. Biomarkers in diabetic nephropathy: A comprehensive review of their role in early detection and disease progression monitoring. Diabetes Res Clin Pract. 2025;226. doi: 10.1016/j.diabres.2025.112292.

Nwanonenyi NV, Ijoma CK, Arodiwe E, Nwanonenyi M-SI, Nebo C. Diagnostic Performance of Cystatin C in the Early Detection of Diabetic Kidney Disease at the University of Nigeria Teaching Hospital, Ituku-Ozalla. Cureus. 2024;16:e72230. doi: 10.7759/CUREUS.72230.

Visinescu AM, Rusu E, Cosoreanu A, Radulian G. CYSTATIN C-A Monitoring Perspective of Chronic Kidney Disease in Patients with Diabetes. Int J Mol Sci. 2024;25(15):8135. doi: 10.3390/IJMS25158135.

Cooper ME, Raalte DH van. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025;135:e194749. doi: 10.1172/JCI194749.

Tommerdahl KL, Kendrick J, Bjornstad P. The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial. Clin J Am Soc Nephrol. 2022;17:905-7. doi: 10.2215/CJN.00020122.

Sasaki T, Giang SM, Wu J, Yokoo T, Gallagher M, Bellomo R, et al. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2026;41(4):681-91. doi: 10.1093/NDT/GFAF193.

Tang H, Li K, Shi Z, Wu J. G-Protein-Coupled Receptors in Chronic Kidney Disease Induced by Hypertension and Diabetes. Cells. 2025;14(10):729. doi: 10.3390/CELLS14100729.

Wei TT, Yang LT, Guo F, Tao SB, Cheng L, Huang RS, et al. Activation of GPR120 in podocytes ameliorates kidney fibrosis and inflammation in diabetic nephropathy. Acta Pharmacol Sin. 2021;42:252-63. doi: 10.1038/S41401-020-00520-4.

Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clin Kidney J. 2024;17(Suppl 2):19-35. doi: 10.1093/CKJ/SFAE296.

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-21. doi: 10.1056/NEJMOA2403347.

Checa-Ros A, Okojie OJ, Wassouf JG, Yedean A, Hsueh WC, Hebda P, et al. Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria. J Pers Med. 2026;16(2):97. doi: 10.3390/JPM16020097.

Mazur T, Demikhova N, Rudenko T, Yurchenko A, Yezhova O, Bokova S, et al. Chronic inflammation and progression of chronic kidney disease in patients with type 2 diabetes. Ukr J Nephr Dial. 2021;4(72):36-43. doi: 10.31450/UKRJND.4(72).2021.05.

Cases A. Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist. Nefrología. 2023;43(4):399-412. doi: 10.1016/J.NEFROE.2023.09.003.

Jang CW, Yu TY, Jeong JW, Ha SE, Singh R, Lee MY, et al. Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus. J Pers Med. 2024;14(3):280. doi: 10.3390/JPM14030280.

Leysen H, Walter D, Christiaenssen B, Vandoren R, Harputluoğlu İ, Van Loon N, et al. GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between Health and Disease. Int J Mol Sci. 2021;22(24):13387. doi: 10.3390/IJMS222413387.

Singh D, Shaker A, Patel TD, Bhaniya MK, Agravatt AM. Evaluation of Serum GPR-120 Levels in Diabetic Patients With and Without Nephropathy: A Comparative Study on Lipid and Renal Parameters. Cureus. 2025;17(6):e85749. doi: 10.7759/CUREUS.85749.


Abstract views: 1
PDF Downloads: 0
Published
2026-08-30
How to Cite
Hassan, A. J., Abdulhadi, G. H., & Hasan, E. J. (2026). Serum glucagon-like peptide-1 and G-protein-coupled receptor levels are associated with albuminuria and kidney function in type 2 diabetes: A cross-sectional study. Ukrainian Journal of Nephrology and Dialysis, (3(91), 25-32. https://doi.org/10.31450/ukrjnd.3(91).2026.04